IP Library Granted Patent US 9,370,469
Granted Patent B2
US 9,370,469 · App. 14/211,994 · Granted Jun 21, 2016

Injectable alloplastic implants and methods of use thereof

Inventor: Louis Masi (Longmeadow, MA)
Assignee: SUNEVA MEDICAL, INC
A61K8/0204A61F2/0059A61K8/65A61K9/0024A61K31/78A61K47/42A61L27/24A61L27/48A61Q19/00A61Q19/08C08L33/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,370,469
App. No.
14/211,994
Granted
Jun 21, 2016
Kind
B2
Abstract

Described herein are injectable alloplastic implant compositions that are particularly useful for soft tissue defect augmentation. The compositions include microparticles, such as polymethylmethacrylate particles, and collagen as a suspending agent, wherein the collagen contains a reduced amount of low molecular weight gelatine compared to high molecular weight collagen. By controlling the molecular weight of the collagen in the compositions, the injectability, stability, and antigenicity of the alloplastic implant compositions can be improved.

Claims (17)

1. A method of augmenting a soft tissue defect, comprising injecting an alloplastic implant composition near the soft tissue defect, wherein the alloplastic implant composition comprises denatured atelocollagen that has less than 10 wt % of the total weight as components of weight average molecular weight (Mw) 100,000 Daltons or lower, and greater than 70 wt % components of weight average molecular weight 100 kDa to 258 kDa,

wherein the polydispersity of the denatured atelocollagen expressed as Mw/Mn is 1.0 to 1.6, wherein Mw is weight average molecular weight and Mn is number average molecular weight.

2. The method of claim 1 , wherein the denatured atelocollagen is in the form of suspending agent having suspended therein microparticles having a diameter of about 5 to about 400 μm.

3. The method of claim 1 , wherein the alloplastic implant composition is injected below the soft tissue defect at a junction of the dermis and subcutaneous fat.

4. The method of claim 1 , wherein the soft tissue defect is a result of aging, a wrinkle, a scar, a deformity related to trauma, or the result of plastic surgery.

5. The method of claim 4 , wherein the soft tissue defect is a nasolabial fold.

6. The method of claim 1 , further comprising repeating injection of the alloplastic implant composition of claim 1 at one or more 2 week intervals.

7. The method of claim 2 , wherein the microparticles of the alloplastic implant composition have a diameter of about 10 to about 200 μm.

8. The method of claim 2 , wherein the microparticles of the alloplastic implant composition have a diameter of about 15 to about 60 μm.

9. The method of claim 2 , wherein the microparticles of the alloplastic implant composition comprise a polymer or copolymer comprising a methacrylate monomer.

10. The method of claim 9 , wherein the polymer or copolymer is polymethylmethacrylate.

11. The method of claim 1 , wherein the alloplastic implant composition is injectable through a 20 to 30 gauge needle.

12. The method of claim 1 , wherein the alloplastic implant composition further comprises a topical anesthetic.

13. The method of claim 1 , wherein the denatured atelocollagen is prepared from bovine or porcine collagen.

14. The method of claim 2 , wherein the denatured atelocollagen is prepared from bovine or porcine collagen.

15. The method of claim 2 , wherein the pH of the aqueous suspending agent is 6.0 to 8.0 and the concentration of denatured atelocollagen in the aqueous suspending agent is 0.5 to 15 wt %.

16. The method of claim 2 , wherein the suspension is stable for at least 30 days at a temperature of 20-25° C.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 22, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: SUNEVA MEDICAL, INC.
Reel/Frame 068968/0598 →
SECURITY INTEREST Recorded Aug 24, 2021
From: SUNEVA MEDICAL, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
Reel/Frame 057277/0460 →
CHANGE OF ASSIGNEE ADDRESS Recorded May 12, 2016
From: SUNEVA MEDICAL, INC.
To: SUNEVA MEDICAL, INC.
Reel/Frame 038688/0378 →
CHANGE OF ASSIGNEE ADDRESS Recorded May 9, 2016
From: SUNEVA MEDICAL, INC.
To: SUNEVA MEDICAL, INC.
Reel/Frame 038641/0985 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2014
From: MASI, LOUIS
To: SUNEVA MEDICAL, INC.
Reel/Frame 032442/0587 →
Continuity (1)
Related Publication 20150257987A1 · Sep 17, 2015